Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 10/20 | 0.42 |
| ▸ | CDK1 | P06493 | 9/20 | 0.42 |
| ▸ | CDK2 | P24941 | 9/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627765 | 0.85 | FLT4 (0.58) | FLT4KDRCDK1CDK2CDK4 | |
| SCHEMBL1627766 | 0.85 | FLT4 (0.58) | FLT4KDRCDK1CDK2CDK4 | |
| SCHEMBL12720382 | 0.85 | FLT4 (0.58) | FLT4KDRCDK1CDK2CDK4 | |
| SCHEMBL1628013 | 0.85 | PTK2 (0.52) | KDRPTK2JAK2NTRK1TYK2 | |
| SCHEMBL30895328 | 0.83 | PTK2 (0.47) | KDRCDK1CDK2CDK4PTK2 | |
| Bromide SCHEMBL30895402 | 0.81 | PTK2 (0.46) | FLT4KDRCDK1CDK2CDK4 | |
| SCHEMBL1008313 | 0.81 | PTK2 (0.53) | KDRPTK2JAK2NTRK1TYK2 | |
| SCHEMBL6509043 | 0.76 | CDK1 (0.61) | FLT4KDRCDK1JAK2 | |
| SCHEMBL15513049 | 0.76 | FLT4 (0.47) | FLT4KDRCDK1CDK2CDK4 | |
| SCHEMBL6033947 | 0.76 | KDR (0.41) | FLT4KDRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885CDK1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.